QQ客服 官方微博 反馈留言

	Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial
	Zhang, Pin; Yin, Yi; Mo, Hongnan; Zhang, Bailin; Wang, Xiang; Li, Qing; Yuan, Peng; Wang, Jiayu; Zheng, Shan; Cai, Ruigang
	2016
卷号	7期号:37页码:60647-60656
关键词	breast cancer triple negative neoadjuvant chemotherapy carboplatin paclitaxel
ISSN号	1949-2553
DOI	10.18632/oncotarget.10607
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6384188
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Zhang, Pin,Yin, Yi,Mo, Hongnan,et al. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial[J],2016,7(37):60647-60656.
APA	Zhang, Pin.,Yin, Yi.,Mo, Hongnan.,Zhang, Bailin.,Wang, Xiang.,...&Xu, Binghe.(2016).Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.,7(37),60647-60656.
MLA	Zhang, Pin,et al."Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial".7.37(2016):60647-60656.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。